- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02407314
Ticagrelor and Peripheral Arterial Disease
Impact of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin in Patients With Claudication and Peripheral Arterial Disease (PAD): Thrombus Burden Assessed by Optical Coherence Tomography
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Prospective, randomized study, comparing ticagrelor + aspirin vs. aspirin monotherapy following the 4-week post-procedural combination of Ticagrelor or Plavix with low dose aspirin. The investigators will enroll a minimum of 40 patients. Patients will be enrolled if they have either claudication and/or critical limb ischemia, and angiographically identified superficial femoral artery (SFA) disease requiring intervention, with either total occlusion or a significant SFA stenosis with the presence of Optical Coherence Tomography (OCT) defined clot following stent placement.
Participants will be evaluated at baseline, 1 month, 4 months, 6 and 7 months following SFA intervention. At baseline demographic data will be collected, and anthropomorphic and physiological variables (body mass index, waist circumference, blood pressure). Baseline and 6-month ankle brachial index (ABI) will be performed. A 6-min walk test will be performed at baseline and 6-month follow-up. At 6 month time point patients in both treatment groups will return for a peripheral angiogram and repeat OCT imaging of the SFA segments of interest. Subject will have a final follow up clinic visit at 7 months.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72211
- Arkansas Heart Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients with lower extremity claudication and PAD due to significant SFA stenosis (>60%) or total occlusions (Rutherford 2-6) that affects the quality of life despite medical therapy.
- The presence of OCT identified clot in the Superficial Femoral Artery (SFA) following stent placement.
- Evidence of significant SFA disease involving the most symptomatic limb established by noninvasive vascular testing (ankle-brachial index [ABI] <0.9, toe brachial Index [TBI] of <0.6. If ABI>1.4, SFA systolic acceleration time >140 milliseconds); computed tomographic angiography, or magnetic resonance angiography confirming at least a 60% stenosis of the SFA.
- At least one non-treated Below The Knee (BTK) vessel patent
- Male and female outpatients 18 years of age.
- The only following devices may be used for the revascularization procedures: conventional balloons and bare metal stents (block randomization).
- Subject has been advised of the beneficial effects of smoking cessation and regular exercise but must not be in the process of changing their smoking status at the time of screening. Patients may resume or increase exercising as an effect of post procedurally improved lower limb perfusion.
- Peak Walking Time (PWT) limited only by claudication.
- Willingness to participate, documented by written informed consent.
Exclusion Criteria:
- Patients requiring dual anti-platelet drug treatment before start of study
- Planned amputation
- Use of atherectomy devices
- Hypersensitivity to acetylsalicylic acid, or ticagrelor. For ticagrelor, hypersensitivity reactions in the past include angioedema
- Patients with known bleeding disorders
- Patients with known active pathological bleeding
- Patients needing chronic oral anticoagulant maintenance therapy
- Patients with a history of intracranial hemorrhage at any time, GI bleed in the past 6 months, or major surgery within the past 30 days
- Ischemic stroke during the past 3 months
- Patients considered to be at risk of bradycardic events unless treated with a permanent pacemaker
- Target is a restenotic lesion or in-stent restenosis
- Any scheduled revascularization procedure requiring dual-anti-platelet therapy for more than one month
- Severe hypertension that may put the patient at risk, systolic greater than or equal to 180 and/or diastolic greater than or equal to 100
- Severe liver disease
- History of congestive heart failure with an Left Ventricular Ejection Fraction (LVEF) of less than 30%
- Concern for inability of the patient to comply with study procedures and/or follow up (eg, alcohol or drug abuse)
- Infra-popliteal disease involving the last remaining vessel (single run-off)
- Prior lower extremity revascularization within the past 30 days prior to enrollment
- Atherectomy of PAD
- EXCIPIENTS to ticagrelor hypersensitivity
- Known pregnancy, breast-feeding, or intend to become pregnant during the study period (all female patients 55 years and younger, without past history of hysterectomy must have a pregnancy test prior to peripheral intervention at baseline and at 6 months)
- Creatinine clearance < 30 mL/min
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador falso: Aspirin only
Clopidogrel 75 mg + aspirin 81 mg for the first month followed by aspirin 81 mg alone for months 2-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT) ankle brachial index (ABI) and six minute walk distance.
|
Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement).
This procedure is considered standard of care and is not experimental.
This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media.
The device used is a cardiac catheter with OCT sensors on the tip of it.
It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms.
The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
Assessment of the walking distance in 6 minutes.
Aspirin, also known as acetylsalicylic acid [ASA], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.
Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
Otros nombres:
|
Experimental: Aspirin + Ticagrelor
ticagrelor 90 mg bid + aspirin 81 mg for months 1-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT)ankle brachial index (ABI) and six minute walk distance.
|
Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement).
This procedure is considered standard of care and is not experimental.
This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media.
The device used is a cardiac catheter with OCT sensors on the tip of it.
It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms.
The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
Assessment of the walking distance in 6 minutes.
This is a combination of drugs (Aspirin + Ticagrelor).
Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor.
Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change in the Intraluminal clot volume (in mm3)
Periodo de tiempo: At baseline and at 6 months
|
Intraluminal clot volume will be assessed by Optical Coherence Tomography using a Core Lab.
|
At baseline and at 6 months
|
Change in the Intraluminal clot length (mm)
Periodo de tiempo: At baseline and at 6 months
|
Intraluminal clotlength will be assessed by Optical Coherence Tomography using a Core Lab.
|
At baseline and at 6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Massoud Leesar, MD, University of Alabama at Birmingham
- Investigador principal: Hinan Ahmed, MD, University of Texas Health Science Center in San Antonio
- Investigador principal: Marc D Feldman, MD, University of Texas Health Science Center in San Antonio
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Arteriosclerosis
- Enfermedades arteriales oclusivas
- Aterosclerosis
- Enfermedad arterial periférica
- Enfermedades vasculares periféricas
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Agentes del sistema nervioso periférico
- Inhibidores de enzimas
- Analgésicos
- Agentes del sistema sensorial
- Agentes antiinflamatorios no esteroideos
- Analgésicos no narcóticos
- Agentes antiinflamatorios
- Agentes antirreumáticos
- Agentes fibrinolíticos
- Agentes moduladores de fibrina
- Inhibidores de la agregación plaquetaria
- Inhibidores de la ciclooxigenasa
- Antipiréticos
- Antagonistas del receptor P2Y purinérgico
- Antagonistas del receptor P2 purinérgico
- Antagonistas purinérgicos
- Agentes Purinérgicos
- Aspirina
- Ticagrelor
Otros números de identificación del estudio
- ESR-14-10020
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedad arterial periférica
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeTerminadoPresión arterial | Anestesia | Línea ArterialEstados Unidos
-
Auburn UniversityActivo, no reclutandoDormir | Presión arterial | Disfunción endotélica | Racismo | Rigidez ArterialEstados Unidos
-
AHEPA University HospitalTerminadoRigidez arterial | Monitoreo ambulatorio de la presión arterialGrecia
-
Unity Health TorontoTerminadoRigidez arterial, presión arterialCanadá
-
CID S.p.A.Meditrial Europe Ltd.Aún no reclutandoEnfermedad arterial periférica oclusiva | Enfermedad Arterial PeriféricaItalia
-
Marissa JarosinskiReclutamientoEnfermedad arterial periférica oclusiva | Enfermedad vascular periférica | Enfermedad Arterial Periférica | Clopidogrel, metabolismo deficiente de | Enfermedad ArterialEstados Unidos
-
ROX Medical, Inc.TerminadoHipertensión | Presión Arterial, Alta | Presión Arterial, Resistente | Presión Arterial, No ControladaReino Unido, Países Bajos, Bélgica
-
Istituto Auxologico ItalianoReclutamientoHipertensión arterial | Monitoreo ambulatorio de la presión arterial | Determinación de la presión arterial | Monitoreo de la presión arterial en el hogarItalia
-
University of JyvaskylaBusiness Finland; Finnish Foundation for Cardiovascular Research; Harvia Finland...TerminadoPresión arterial | Factor de riesgo cardiovascular | Rigidez arterialFinlandia
-
University of NebraskaAún no reclutandoEnfermedad arterial periférica | Enfermedades vasculares periféricas | Enfermedad arterial periférica oclusiva | Enfermedad Arterial PeriféricaEstados Unidos
Ensayos clínicos sobre Percutaneous Peripheral Intervention
-
ID3 MedicalActivo, no reclutandoEnfermedad arterial periféricaBélgica, Francia
-
University of OxfordOxford University Hospitals NHS TrustDesconocidoSíntomas de comportamientoReino Unido
-
Avantec VascularBright Research Partners; Yale Cardiovascular Research GroupAún no reclutandoEnfermedad arterial periférica
-
Shiraz University of Medical SciencesTerminado
-
Heidelberg UniversityDesconocidoRetraso de idioma | Trastornos del desarrollo del lenguajeAlemania
-
Munich Municipal HospitalTechnical University of Munich; University of RegensburgDesconocido
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR)Activo, no reclutandoDependencia a la nicotina, cigarrillos | Abstinencia de nicotinaCanadá
-
Dr. Sabrina OverhagenActivo, no reclutandoAneurisma de la aorta toracoabdominal, sin mención de rotura | Aneurisma aórtico abdominal, sin mención de rupturaAlemania
-
IWK Health CentreCanadian Institutes of Health Research (CIHR)TerminadoTrastorno de oposición desafiante | Trastorno de conductaCanadá
-
The Hospital for Sick ChildrenTerminadoObesidad infantilCanadá